| Title |
Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2015
|
| DOI | 10.2147/dddt.s83144 |
| Pubmed ID | |
| Authors |
Mohammed S Ellulu, Asmah Rahmat, Ismail Patimah, Huzwah Khaza’ai, Yehia Abed |
| Abstract |
Obesity is well associated as being an interfering factor in metabolic diseases such as hypertension and diabetes by increasing the secretion of proinflammatory markers from adipose tissue. Having healthy effects, vitamin C could work as an anti-inflammatory agent through its antioxidant capacity. FPSK_Mac [13]04. The aim of the study reported here was to identify the effect of vitamin C on reducing the levels of inflammatory markers in hypertensive and/or diabetic obese adults. Sixty-four obese patients, who were hypertensive and/or diabetic and had high levels of inflammatory markers, from primary health care centers in Gaza City, Palestine, were enrolled into one of two groups in an open-label, parallel, randomized controlled trial. A total of 33 patients were randomized into a control group and 31 patients were randomized into an experimental group. The experimental group was treated with 500 mg vitamin C twice a day. In the experimental group, vitamin C significantly reduced the levels of high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), fasting blood glucose (FBG), and triglyceride (TG) after 8 weeks of treatment (overall: P<0.001); no changes appeared in total cholesterol (TC). In the control group, there were significant reductions in FBG and TG (P=0.001 and P=0.026, respectively), and no changes in hs-CRP, IL-6, or TC. On comparing the changes in the experimental group with those in the control group at the endpoint, vitamin C was found to have achieved clinical significance in treating effectiveness for reducing hs-CRP, IL-6, and FBG levels (P=0.01, P=0.001, and P<0.001, respectively), but no significant changes in TC or TG were found. Vitamin C (500 mg twice daily) has potential effects in alleviating inflammatory status by reducing hs-CRP, IL-6, and FBG in hypertensive and/or diabetic obese patients. |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 16% |
| India | 3 | 9% |
| Japan | 2 | 6% |
| Canada | 2 | 6% |
| Australia | 1 | 3% |
| Uruguay | 1 | 3% |
| Armenia | 1 | 3% |
| Unknown | 17 | 53% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 75% |
| Scientists | 6 | 19% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
| Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 344 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 2 | <1% |
| Chile | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 340 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 70 | 20% |
| Student > Master | 38 | 11% |
| Student > Ph. D. Student | 26 | 8% |
| Researcher | 21 | 6% |
| Other | 20 | 6% |
| Other | 43 | 13% |
| Unknown | 126 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 87 | 25% |
| Nursing and Health Professions | 41 | 12% |
| Agricultural and Biological Sciences | 23 | 7% |
| Biochemistry, Genetics and Molecular Biology | 22 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 2% |
| Other | 28 | 8% |
| Unknown | 135 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 123. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2024.
All research outputs
#347,565
of 25,826,146 outputs
Outputs from Drug Design, Development and Therapy
#27
of 2,284 outputs
Outputs of similar age
#3,577
of 278,412 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 156 outputs
Altmetric has tracked 25,826,146 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,412 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 156 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.